Clinical Trial Update: PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance [Phase 2]

View source ↗

Summary

Phase 2 trial assessing PROSTVAC (PSA-TRICOM) for preventing disease progression in localized prostate cancer patients on active surveillance; study completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Prostvac (PROSTVAC)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7 | Phase 2 | Status: COMPLETED | Results posted: 2021-11-02